State Street Investment Management has upgraded its healthcare sector outlook from neutral to positive for Q3 2026, citing expected earnings growth of 19.3% in 2027, driven by biopharma innovations and stabilizing managed care trends. Despite recent buying, institutional investors remain underweight in healthcare, which is currently valued at its cheapest level in 15 years. Key advancements in obesity treatments, Alzheimer’s research, gene editing, and cancer therapies support optimism, although risks like drug pricing policy uncertainty and soft demand for medical technology persist. Investors can access this opportunity through ETFs like XLV and XLVI, which offer exposure and income strategies in healthcare stocks.
